Article
AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.
Biochemical and biophysical research communications - 15 Jul 2017
Wang Hongbin, Quan Haitian, Lou Liguang
Abstract excerpt
BRAF, one of the key factors in mitogen-activated protein kinase (MAPK) signaling pathway, plays an important role in cell functions including growth and proliferation. Inhibition of BRAF represents a promising antitumor strategy. Dabrafenib, a type I inhibitor of BRAF interrupting RAF/MEK interaction, has been approved by FDA as a single agent or combined with MEK inhibitor trametinib for the treatment of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.